ETON News and Press, Eton Pharmaceutcials Inc. From 05/11/23

2023-05-11 16:04:53 ET Eton Pharmaceuticals press release ( NASDAQ: ETON ): Q1 GAAP EPS of -$0.10 beats by $0.04 . Revenue of $5.3M (+143.1% Y/Y) beats by $0.74M . For further details see: Eton Pharmaceuticals GAAP EPS of -$0.10 beats by $0.04, revenue of...

Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or ...

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -- -- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical compa...

DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2...

2023-03-20 04:55:13 ET Summary The addition of a new sales force could be a catalyst that drives the performance of the company in the near term. Expectations are sales will increase with little impact on expenses because of offsetting factors. With the recent jump in its shar...

2023-03-16 17:48:02 ET Eton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Conference Call March 16, 2023, 04:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Jame...

2023-03-16 16:10:58 ET Eton Pharmaceuticals press release ( NASDAQ: ETON ): Q4 GAAP EPS of $0.04 beats by $0.03 . Revenue of $8.5M (+39.6% Y/Y) misses by $0.62M . Gross Profit: Gross profit for the fourth quarter of 2022 was $6.4 million compared with $5.7 mi...

Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton&#x...

-- Product is targeting rare pediatric endocrinology condition -- -- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company...

DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March ...